Grifols, S.A. (GRFS)
GRFS Stock Price Chart
Explore Grifols, S.A. interactive price chart. Choose custom timeframes to analyze GRFS price movements and trends.
GRFS Company Profile
Discover essential business fundamentals and corporate details for Grifols, S.A. (GRFS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
2 Jun 2011
Employees
23.83k
Website
https://www.grifols.comCEO
Jose Ignacio Abia Buenache
Description
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
GRFS Financial Timeline
Browse a chronological timeline of Grifols, S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Jul 2026
EPS estimate is $0.28, while revenue estimate is $2.22bn.
Dividend declared on 2 Jul 2026
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 9 Jul 2026.
Earnings released on 7 May 2026
EPS came in at $0.17 surpassing the estimated $0.16 by +7.32%, while revenue for the quarter reached $2.00bn , missing expectations by -1.45%.
Earnings released on 26 Feb 2026
EPS came in at $0.29 falling short of the estimated $0.29 by -0.31%, while revenue for the quarter reached $2.34bn , missing expectations by -0.20%.
Earnings released on 4 Nov 2025
EPS came in at $0.22 falling short of the estimated $0.24 by -9.60%, while revenue for the quarter reached $2.18bn , beating expectations by +1.49%.
Dividend declared on 12 Aug 2025
A dividend of $0.18 per share was announced, adjusted to $0.18. The dividend was paid on 20 Aug 2025.
Earnings released on 28 Jul 2025
EPS came in at $0.19 falling short of the estimated $0.23 by -17.39%, while revenue for the quarter reached $2.23bn , beating expectations by +19.77%.
Earnings released on 12 May 2025
EPS came in at $0.10 falling short of the estimated $0.14 by -28.57%, while revenue for the quarter reached $1.96bn , beating expectations by +13.13%.
Earnings released on 6 Mar 2025
EPS came in at $0.26 surpassing the estimated $0.13 by +100.00%, while revenue for the quarter reached $2.05bn , beating expectations by +6.49%.
Earnings released on 7 Nov 2024
EPS came in at $0.16 falling short of the estimated $0.22 by -27.27%, while revenue for the quarter reached $1.97bn , missing expectations by -3.15%.
Earnings released on 30 Jul 2024
EPS came in at $0.02 falling short of the estimated $0.23 by -91.30%, while revenue for the quarter reached $1.95bn , beating expectations by +3.96%.
Earnings released on 14 May 2024
EPS came in at $0.07 falling short of the estimated $0.15 by -53.33%, while revenue for the quarter reached $1.76bn , missing expectations by -10.05%.
Earnings released on 5 Mar 2024
EPS came in at $0.14 falling short of the estimated $0.22 by -36.36%, while revenue for the quarter reached $1.95bn , beating expectations by +1.65%.
Earnings released on 2 Nov 2023
EPS came in at $0.11 falling short of the estimated $0.22 by -50.00%, while revenue for the quarter reached $1.69bn , beating expectations by +0.15%.
Earnings released on 27 Jul 2023
EPS came in at $0.09 falling short of the estimated $0.20 by -54.80%, while revenue for the quarter reached $1.81bn , missing expectations by -2.17%.
Earnings released on 16 May 2023
EPS came in at -$0.02 falling short of the estimated $0.16 by -110.67%, while revenue for the quarter reached $1.68bn , missing expectations by -0.61%.
Earnings released on 13 Mar 2023
EPS came in at $0.03 falling short of the estimated $0.24 by -86.73%, while revenue for the quarter reached $1.84bn .
Earnings released on 27 Feb 2023
EPS came in at $0.06 falling short of the estimated $0.24 by -73.29%, while revenue for the quarter reached $1.51bn .
Earnings released on 28 Jul 2022
EPS came in at $0.14 falling short of the estimated $0.29 by -52.25%, while revenue for the quarter reached $1.61bn , missing expectations by -42.41%.
Earnings released on 5 May 2022
Earnings released on 28 Feb 2022
EPS came in at -$0.13 falling short of the estimated $0.24 by -155.08%, while revenue for the quarter reached $2.69bn , missing expectations by -5.03%.
Earnings released on 30 Dec 2021
EPS came in at $0.36 .
Earnings released on 29 Jul 2021
EPS came in at $0.35 surpassing the estimated $0.27 by +29.63%, while revenue for the quarter reached $1.60bn , missing expectations by -46.50%.
GRFS Stock Performance
Access detailed GRFS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
